Where is compounded semaglutide made? (503A vs 503B pharmacies)

The storefront may not be the compounder

Enrollment, prescribing, compounding and dispensing can involve different organizations. A telehealth company can provide the website and program support while a clinical organization evaluates the request and a pharmacy prepares and ships the prescription. FDA’s compounding guidance notes that online patients may not know the compounder’s identity. Identify that entity rather than assuming the name on the enrollment page is the legal pharmacy name. [1]

Ask which organization compounds the preparation and which pharmacy dispenses it to you. If there are multiple partners, ask which one is assigned to the actual product and location. A partner list describes possible relationships, not the specific origin of every patient order. Retain the pharmacy’s name with the prescription information so a product question reaches the responsible entity rather than remaining in the storefront’s general support queue. [4][1]

What 503A identifies

FDA describes 503A as the framework for human-drug compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, outside the registered outsourcing-facility category. The pathway includes conditions such as the individual-patient prescription requirement. It is a legal framework with specified exemptions, not a seal of approval attached to every preparation. [2]

State pharmacy boards generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered outsourcing facilities. FDA can also conduct surveillance or for-cause inspections. Saying a pharmacy is overseen by a state does not mean federal requirements disappear, and saying a facility was inspected does not establish that each prescription it produces has been reviewed or approved by FDA. [1]

What 503B identifies

Outsourcing facilities register with FDA under 503B and are subject to current good manufacturing practice requirements and FDA inspection on a risk-based schedule. The framework differs from 503A in several ways, including how individual prescriptions and bulk substances are handled. FDA’s comparison is a useful starting point for understanding the category, but it explicitly does not replace the full applicable requirements. [1][2]

FDA publishes a registered-outsourcing-facility list with identifying details and dates. Use the current list to check a claimed registration, matching the actual facility identity rather than a similar business name. Registration identifies the facility category; it does not establish approval of compounded semaglutide or permission to use a particular bulk substance. Product eligibility still needs the relevant rule and source checked. [3][5]

Why GLP-1 bulk rules matter even at a registered facility

FDA’s April 2026 reminder states that semaglutide and tirzepatide are not currently on the 503B bulks list or drug shortage list. It describes the constraints on outsourcing facilities using bulk drug substances. A facility’s presence on a registration list cannot be substituted for a substance’s presence on an eligibility list. The two lists answer different questions. [6][5]

For 503A, the same reminder discusses patient-specific compounding and restrictions on essentially copying commercial products. The relevant pharmacy and prescriber must explain the arrangement for the actual preparation. A statement that a pharmacy is licensed or that a product is customized is incomplete evidence of those conditions. Our legal-framework guide covers the current distinctions without adjudicating a particular prescription. [6]

Use official identity and inspection records carefully

FDA’s compounding actions page includes inspections, recalls and other records. Match the entity, facility location, date and product scope before connecting an entry to a provider’s pharmacy partner. A record concerning one facility or batch should not be silently generalized to all organizations with similar names or all products under a telehealth brand. The page supplies regulatory evidence, not a ranked list of pharmacies. [7]

Likewise, an entry absent from one FDA list does not settle all licensing or oversight questions. A state-licensed 503A pharmacy is not the same category as a registered 503B outsourcing facility. Check the relevant state board when verifying pharmacy licensing and use the FDA facility list for the registration claim it actually covers. An incomplete search should not be reported as proof that an organization has no license or inspection history anywhere. [4][2][3]

What the patient-facing label should help identify

Use the pharmacy’s dispensing information to establish whom to contact about the preparation. FDA has reported fraudulent compounded GLP-1 labels naming nonexistent pharmacies or pharmacies that did not make the product. A familiar or plausible name on an advertisement is therefore not enough to authenticate a specific package. Bring a discrepancy to the named pharmacy and prescribing team through their official channels. [8]

The directory records pharmacy information when supported by the provider’s primary sources and preserves limitations when it is not established. It does not inspect facilities or authenticate individual medication contents. The practical outcome of this guide is a clear service chain: the clinical organization, actual compounder and dispensing pharmacy, with the relevant official identity checks. Regulatory category remains distinct from FDA approval of a finished drug. [1][4]

Where the ingredient came from is a different question

The location of the pharmacy preparing the finished medication does not by itself identify the source of its active pharmaceutical ingredient. FDA’s GLP-1 concerns page discusses imported ingredients and its green-list import alert. That is a supply-chain distinction, not approval of a compounded finished product. If a company makes a country-of-origin claim, ask whether it concerns the ingredient manufacturer, compounder or dispensing pharmacy. A US pharmacy address should not be silently translated into a claim that every part of the production chain occurred there. [8]